Search

Dogs with lower airway pathology that present in respiratory distress often receive oxygen therapy as the first line of treatment regardless of the underlying cause. Conventional "low-flow" systems deliver oxygen with a maximum flow rate of 15 L/minute. Traditionally, when an animal's respiratory status does not improve with conventional oxygen therapy and treatments for underlying disease, options might be limited to either intubation and mechanical ventilation or humane euthanasia. High-flow oxygen therapy (HFOT) has been gaining popularity in veterinary medicine as an alternative route of oxygen supplementation for animals that require support beyond conventional therapy. High-flow oxygen therapy can supply a mixture of air and oxygenLes chiens avec une pathologie des voies respiratoires inférieures qui présentent une détresse respiratoire reçoivent souvent une oxygénothérapie en première intention, quelle que soit la cause sous-jacente. Les systèmes conventionnels à « faible débit » fournissent de l’oxygène avec un débit maximum de 15 L/minute. Traditionnellement, lorsque l’état respiratoire d’un animal ne s’améliore pas avec l’oxygénothérapie conventionnelle et les traitements de la maladie sous-jacente, les options peuvent se limiter à l’intubation et à la ventilation mécanique ou à l’euthanasie. L’oxygénothérapie à haut débit (HFOT) gagne en popularité en médecine vétérinaire en tant que voie alternative de supplémentation en oxygène pour les animaux qui nécessitent un soutien au-delà de la thérapie conventionnelle. L’oxygénothérapie à haut débit peut fournir un mélange d’air et d’oxygène

Objective—To determine whether lipid particle coalescence develops in veterinary parenteral nutrition (PN) admixture preparations that are kept at room temperature (23°C) for > 48 hours and whether that coalescence is prevented by admixture filtration, refrigeration, or agitation. Sample Population—15 bags of veterinary PN solutions. Procedures—Bags of a PN admixture preparation containing a lipid emulsion were suspended and maintained under different experimental conditions (3 bags/group) for 96 hours while admixtures were dispensed to simulate IV fluid administration (rate, 16 mL/h). Bags were kept static at 4°C (refrigeration); kept at 23°C (room temperature) and continuously agitated; kept at room temperature and agitated for 5 minutes every 4 hours; kept static at room temperature and filtered during delivery; or kept static at room temperature (control conditions). Admixture samples were collected at 0, 24, 48, 72, and 96 hours and examined via transmission electron microscopy to determine lipid particle diameters. At 96 hours, 2 samples were collected at a location distal to the filter from each bag in that group for bacterial culture. Results—Distribution of lipid particle size in the control preparations and experimentally treated preparations did not differ significantly. A visible oil layer developed in continuously agitated preparations by 72 hours. Bacterial cultures of filtered samples yielded no growth. Conclusions and Clinical Relevance—Data indicated that the veterinary PN admixtures kept static at 23°C are suitable for use for at least 48 hours. Manipulations of PN admixtures appear unnecessary to prolong lipid particle stability, and continuous agitation may hasten lipid breakdown.

Decreased caloric and other nutrient intake can complicate the course of both mild and serious illness. With proper case selection, providing parenteral nutrition (PN) can improve clinical outcome, reduce hospitalization time, and reduce the cost of patient care. Many pharmacy facilities can compound PN formulations; with proper staff training and patient monitoring resources, PN can be administered in many veterinary practices. This article discusses the components of PN formulations as well as the criteria for rational selection of patients to receive PN.